Effect of atorvastatin on TH1 and TH2 cytokine secreting cells during T cell activation and differentiation

Atherosclerosis

Volumn 186, Issue 2, 2006, Pages 302-309

  Coward, William ^a   Chow, Sek C ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

IFN ; IL 4; Immunomodulation; PHA; Statins; T cells; T helper 1; T helper 2

Indexed keywords

ATORVASTATIN; CD3 ANTIBODY; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; MONOCLONAL ANTIBODY CD28; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; PYRROLE DERIVATIVE;

ARTICLE; CD4 CD8 RATIO; CELL CULTURE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOMODULATION; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; CELL DEATH; CYTOLOGY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; SECRETION;

ANTICHOLESTEREMIC AGENTS; CELL DEATH; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; HEPTANOIC ACIDS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; PYRROLES; TH1 CELLS; TH2 CELLS;

EID: 33645968887     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.08.013     Document Type: Article

References (34)

1. Hebert P.R., Gaziano J.M., Chan K.S., and Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278 (1997) 313-321
2. Pedersen T.R. Statin trials and goals of cholesterol-lowering therapy after AMI. Am Heart J 138 (1999) S177-S182
3. Vaughan C.J., Gotto Jr. A.M., and Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35 (2000) 1-10
4. Brown B.G., Zhao X.Q., Sacco D.E., and Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87 (1993) 1781-1791
5. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335 (1996) 1001-1009
6. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
7. Smilde T.J., van Wissen S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 (2001) 577-581
8. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 6 (2000) 1399-1402
9. Weitz-Schmidt G., Welzenbach K., Brinkmann V., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 (2001) 687-692
10. Reape T.J., and Groot P.H. Chemokines and atherosclerosis. Atherosclerosis 147 (1999) 213-225
11. Youssef S., Stuve O., Patarroyo J.C., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84
12. H1 cells through atorvastatin. J Exp Med 197 (2003) 725-733
13. Leung B.P., Sattar N., Crilly A., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170 (2003) 1524-1530
14. Sallusto F., Mackay C.R., and Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277 (1997) 2005-2007
15. Asselin S., Conjeaud H., Minty A., Fradelizi D., and Breban M. Stable polarization of peripheral blood T cells towards type 1 or type 2 phenotype after polyclonal activation. Eur J Immunol 28 (1998) 532-539
16. + T cells based on cytokine secretion. Methods 31 (2003) 150-159
17. LeBlanc R., Hideshima T., Catley L.P., et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103 (2004) 1787-1790
18. Desombere I., Meuleman P., Rigole H., et al. The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level. J Immunol Meth 286 (2004) 167-185
19. Neuhaus O., Strasser-Fuchs S., Fazekas F., et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59 (2002) 990-997
20. + T cells secreting Th1 or Th2 cytokines. Immunity 2 (1995) 271-279
21. Palinski W., and Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 13 (2002) 1673-1681
22. Mestas J., and Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 172 (2004) 2731-2738
23. Vollmer T., Key L., Durkalski V., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
24. Kwak B.R., Mulhaupt F., and Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2 (2003) 332-338
25. Steinman L., Rosenbaum J.T., Sriram S., and McDevitt H.O. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci USA 78 (1981) 7111-7114
26. Waldor M.K., Sriram S., McDevitt H.O., and Steinman L. In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc Natl Acad Sci USA 80 (1983) 2713-2717
27. Vladutiu A.O., and Steinman L. Inhibition of experimental autoimmune thyroiditis in mice by anti-I-A antibodies. Cell Immunol 109 (1987) 169-180
28. Reiss Y., and Engelhardt B. T cell interaction with ICAM-1-deficient endothelium in vitro: transendothelial migration of different T cell populations is mediated by endothelial ICAM-1 and ICAM-2. Int Immunol 11 (1999) 1527-1539
29. Rosenson R.S. Current overview of statin-induced myopathy. Am J Med 116 (2004) 408-416
30. Jamal S.M., Eisenberg M.J., and Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 147 (2004) 956-965
31. Chang J.T., Staffa J.A., Parks M., and Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 13 (2004) 417-426
32. Landesman K.A., Stozek M., and Freeman N.J. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Conn Med 63 (1999) 455-457
33. Mah Ming J.B., and Gill M.J. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS 17 (2003) 207-210
34. Barry M. Rosuvastatin-warfarin drug interaction. Lancet 363 (2004) 328